# Palliation in advanced triple-negative breast cancer: brain, bone, pleura, skin and end of life

Source: https://onco.cc/terms/tnbc-symptom-control-palliation/  
OnCo record `tnbc-symptom-control-palliation` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Advanced triple-negative breast cancer spreads early to the brain, lungs, liver and bones. Brain metastases get focused radiotherapy or surgery, bone pain a single dose of radiotherapy and bone-protecting drugs, fluid around the lung drainage or a permanent tube, skin disease radiotherapy; palliative care alongside cancer treatment from the start is the standard.

## Summary

Brain metastases occur in about 29 percent of patients with metastatic triple-negative disease in a 433-patient single-centre series (cumulative incidence 17 percent at one year and 25 percent at two; median survival 7.3 months after diagnosis), and in the KEYNOTE-522 RCB analysis more than half of relapses after a pathological complete response or minimal residual disease were in the central nervous system. Local treatment follows the general breast cancer rules: stereotactic radiosurgery for a limited number of lesions, surgery for a large symptomatic lesion, whole-brain radiotherapy for widespread disease, with dexamethasone for oedema. Drug activity in the brain is emerging rather than proven: in ASCENT (12 percent of patients had stable brain metastases) progression-free survival was numerically longer with sacituzumab govitecan but overall survival was similar to chemotherapy; a 26-patient German real-world series found an intracranial disease control rate of 42 percent with sacituzumab govitecan and 88 percent with trastuzumab deruxtecan; and the DEBBRAH trial reported a median overall survival of 13.3 months with trastuzumab deruxtecan in seven patients with HER2-positive or HER2-low leptomeningeal disease. TUXEDO-4 (trastuzumab deruxtecan, HER2-low, active brain metastases) is recruiting.

Bone metastases are less common than in hormone-receptor-positive disease but are treated the same way: single-fraction palliative radiotherapy for pain, denosumab or zoledronic acid to reduce skeletal events, urgent imaging and radiotherapy or surgery for spinal cord compression. Malignant pleural effusion is drained, with talc pleurodesis or an indwelling pleural catheter for recurrence. Chest wall and skin recurrence, more frequent in triple-negative disease, is treated with radiotherapy and wound care. Hand-foot syndrome (73 percent of patients on capecitabine in CREATE-X), neutropenia and diarrhoea (grade 3 or higher in 51 and 10 percent on sacituzumab govitecan in ASCENT), stomatitis and eye symptoms (datopotamab deruxtecan) and interstitial lung disease (12.1 percent any grade, 0.8 percent fatal with trastuzumab deruxtecan in DESTINY-Breast04) are the drug toxicities that most often need supportive management. Early integrated palliative care is recommended by the ESMO metastatic breast cancer guideline; there is no triple-negative-specific supportive care trial.

## Fields

- Kind: Term
- Last checked: 2026-09-24
- Also known as: TNBC palliative care; Supportive care in metastatic TNBC

## Sources

- Incidence, pattern and prognosis of brain metastases in metastatic TNBC (BMC Cancer 2018, 433 patients): https://doi.org/10.1186/s12885-018-4371-0
- Sacituzumab govitecan and trastuzumab deruxtecan in stable and active brain metastases: multicentre real-world analysis (ESMO Open 2024): https://doi.org/10.1016/j.esmoop.2024.102995
- DEBBRAH cohort 5: trastuzumab deruxtecan in leptomeningeal disease (Med 2025): https://doi.org/10.1016/j.medj.2024.08.001
- ESMO metastatic breast cancer guideline (Annals of Oncology 2021): https://doi.org/10.1016/j.annonc.2021.09.019

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Early integrated palliative care](https://onco.cc/technologies/palliative-care/), [Hypofractionated radiotherapy](https://onco.cc/technologies/hypofractionated-radiotherapy/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Denosumab](https://onco.cc/drugs/denosumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Zoledronic acid](https://onco.cc/drugs/zoledronic-acid/)
- terms: [Bone metastases and skeletal-related events](https://onco.cc/terms/bone-metastases/), [Brain metastases (intracranial disease)](https://onco.cc/terms/brain-metastases/), [Hand-foot syndrome and hand-foot skin reaction](https://onco.cc/terms/hand-foot-syndrome/), [Interstitial lung disease (ILD) / pneumonitis](https://onco.cc/terms/ild/), [Leptomeningeal disease](https://onco.cc/terms/leptomeningeal-disease/), [Neutropenia](https://onco.cc/terms/neutropenia/), [Stereotactic radiosurgery (SRS)](https://onco.cc/terms/stereotactic-radiosurgery/), [Whole-brain radiotherapy (WBRT)](https://onco.cc/terms/wbrt/)
- trials: [ASCENT](https://onco.cc/trials/ascent/), [DESTINY-Breast04](https://onco.cc/trials/destiny-breast04/), [KEYNOTE-522](https://onco.cc/trials/keynote-522/)

---
JSON: https://onco.cc/api/v1/entities/tnbc-symptom-control-palliation.json